- Home
- LXEH vs ALGS Comparison
LXEH vs ALGS Comparison
Compare LXEH & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | ALGS |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | China | United States |
| Employees | 192 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 57.2M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LXEH | ALGS |
|---|---|---|
| Price | $0.32 | $9.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 236.5K | 76.5K |
| Earning Date | 12-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,585,942.00 | $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $3.76 |
| 52 Week High | $50.08 | $46.80 |
Technical Indicators
Market Signals| Indicator | LXEH | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 62.82 |
| Support Level | $0.31 | $9.10 |
| Resistance Level | $0.37 | $10.45 |
| Average True Range (ATR) | 0.03 | 0.69 |
| MACD | 0.03 | 0.25 |
| Stochastic Oscillator | 18.36 | 87.93 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.